The Glioblastoma Pipeline Insight 2023 report by DelveInsight offers a thorough global overview of Glioblastoma treatments, including those already in the market, as well as those in different phases of clinical development. Prominent pharmaceutical firms are dedicated to progressing the Glioblastoma pipeline landscape and fostering the potential growth of Glioblastoma therapeutic advancements.

 

Key Takeaways from the Glioblastoma Pipeline Report

• DelveInsight’s Glioblastoma pipeline report depicts a robust space with 195+ active players working to develop 210+ pipeline therapies for Glioblastoma treatment.
• The leading companies working in the Glioblastoma market include Denovo BioPharma, Pfizer, Vigeo Therapeutics, Celldex Therapeutics, Debiopharm, Prelude Therapeutics, AiVita Biomedical, Ascletis Pharma, Kintara Therapeutics, Bayer AG, Kazia Therapeutics, GlaxoSmithKline, Candel Therapeutics, Symphogen A/S, Sanofi, Oblato, Jiangsu Hengrui Medicine, BPGbio, Inc., Alaunos Therapeutics, Eli Lilly and Company, Actuate Therapeutics, Oncotelic Therapeutics, The Menarini Group, SonALAsense, Novartis, Allarity Therapeutics, PharmAbcine, I-Mab Biopharma Co. Ltd., Aadi Bioscience Inc., Matrix Biomed, Photonamic GmbH & Co. KG, Lixte, Black Diamond Therapeutics, Tmunity Therapeutics, SOM Biotech, Moleculin, Xynomic Pharmaceuticals, OncoSynergy, and others.
• Promising Glioblastoma Pipeline Therapies in the various stages of development include multiple dose of EO2401, PLX3397, Temozolomide, Temozolomide, VXM01, Avelumab, Cilengitide, Temozolomide, APVAC1 vaccine plus Poly-ICLC and GM-CSF, ACT001, LAM561, Onfekafusp alfa, and others.
• On February 2023, Enterome announced a study of Phase 1 & 2 clinical trials for Multiple dose of EO2401. The purpose of this study is to assess the safety, tolerability, immunogenicity, and preliminary efficacy of EO2401 in patients with unequivocal evidence of progressive or first recurrent glioblastoma.
• On February 2023, Laminar Pharmaceuticals announced a study of Phase 2 & 3 clinical trials for LAM561 and TMZ. The proposed Phase IIB/III randomized, double-blind, placebo-controlled trial in subjects with newly diagnosed primary glioblastoma multiforme (ndGBM) aims to compare the efficacy and safety of LAM561 versus placebo, given with standard of care (SoC) therapy of radiation therapy plus temozolomide (TMZ), followed by an adjuvant treatment of 6 month period of TMZ and then LAM561 or placebo in monotherapy.
• On May 2023, Inovio Pharmaceuticals announced a study of Phase 1 & 2 clinical trials for INO-5401 and INO-9012. Phase 1/2 trial to evaluate safety, immunogenicity and preliminary efficacy of INO-5401 and INO-9012 in combination with cemiplimab (REGN2810), with radiation and chemotherapy, in subjects with newly-diagnosed glioblastoma (GBM).
• On August 2023, Chimeric Therapeutics announced a study of Phase 1 clinical trials for CHM-1101 CAR-T Cells. This is a phase 1b study to evaluate the safety of chimeric antigen receptor (CAR) T cells with a chlorotoxin tumor-targeting domain (ie, CHM-1101, the study treatment) to determine the best dose of CHM-1101, and to assess the effectiveness of CHM-1101 in treating MMP2+ glioblastoma that has come back (recurrent) or that is growing, spreading, or getting worse (progressive).

 

Request a sample and discover the recent advances in Glioblastoma Treatment Drugs @ Glioblastoma Infection Pipeline Report

 

The Glioblastoma pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Glioblastoma drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Glioblastoma clinical trial landscape.

 

Glioblastoma Overview

Glioblastoma Multiforme (GBM) is the most frequently occurring type of primary tumor of the central nervous system (CNS) mostly in adults, and its poor prognosis has not been significantly improved despite the fact that innovative diagnostic strategies and new therapies have been developed.

 

Find out more about Glioblastoma Treatment Drugs @ Drugs for Glioblastoma Treatment

 

Glioblastoma Emerging Drugs Profile

• Enzastaurin: Denovo BioPharma
• Tofacitinib: Pfizer
• VT1021: Vigeo Therapeutics
• Varlilumab: Celldex Therapeutics
• Debio 0123: Debiopharm
• PRT3645: Prelude Therapeutics

 

Glioblastoma Pipeline Therapeutics Assessment

The Glioblastoma pipeline report proffers an integral view of the Glioblastoma emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.

 

Learn more about the emerging Glioblastoma Pipeline Therapies @ Glioblastoma Clinical Trials Assessment

 

Scope of the Glioblastoma Pipeline Report

• Coverage- Global
• Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Glioblastoma Companies- Denovo BioPharma, Pfizer, Vigeo Therapeutics, Celldex Therapeutics, Debiopharm, Prelude Therapeutics, AiVita Biomedical, Ascletis Pharma, Kintara Therapeutics, Bayer AG, Kazia Therapeutics, GlaxoSmithKline, Candel Therapeutics, Symphogen A/S, Sanofi, Oblato, Jiangsu Hengrui Medicine, BPGbio, Inc., Alaunos Therapeutics, Eli Lilly and Company, Actuate Therapeutics, Oncotelic Therapeutics, The Menarini Group, SonALAsense, Novartis, Allarity Therapeutics, PharmAbcine, I-Mab Biopharma Co. Ltd., Aadi Bioscience Inc., Matrix Biomed, Photonamic GmbH & Co. KG, Lixte, Black Diamond Therapeutics, Tmunity Therapeutics, SOM Biotech, Moleculin, Xynomic Pharmaceuticals, OncoSynergy, and others.
• Glioblastoma Pipeline Therapies- multiple doses of EO2401, PLX3397, Temozolomide, Temozolomide, VXM01, Avelumab, Cilengitide, Temozolomide, APVAC1 vaccine plus Poly-ICLC and GM-CSF, ACT001, LAM561, Onfekafusp alfa, and others.

 

Dive deep into rich insights for new drugs for Glioblastoma treatment, Visit @ Glioblastoma Market Drivers and Barriers, and Future Perspective

 

Table of Content

1. Introduction
2. Executive Summary
3. Glioblastoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Glioblastoma– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Enzastaurin: Denovo BioPharma
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Varlilumab: Celldex Therapeutics
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. PRT3645: Prelude Therapeutics
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. ELC-401: Elicera Therapeutics
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Glioblastoma Key Companies
21. Glioblastoma Key Products
22. Glioblastoma- Unmet Needs
23. Glioblastoma- Market Drivers and Barriers
24. Glioblastoma- Future Perspectives and Conclusion
25. Glioblastoma Analyst Views
26. Glioblastoma Key Companies
27. Appendix

 

For further information on the Glioblastoma pipeline therapeutics, reach out to Glioblastoma Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/ci-tracking